Overview

Divalproex Sodium ER in Adult Autism

Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
12-week open label treatment trial of divalproex sodium extended release (Depakote ER) in 10 patients with a diagnosis of autism. Our objective is to determine how well these patients can tolerate the prescribed doses and what added benefits can be attributed to divalproex sodium ER.
Phase:
Phase 4
Details
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Montefiore Medical Center
Treatments:
Valproic Acid